Xeris Biopharma Shares Climb 12% on Amgen License Agreement
By Ben Glickman
Shares of Xeris Biopharma rose Wednesday after the company reached a license agreement with Amgen involving its XeriJect technology.
The stock was up 12% to $2.67 in morning trading. Shares have more than doubled in the last year.
Amgen shares were roughly flat in morning trading.
Chicago-based Xeris said Wednesday morning that Amgen would develop, manufacture and commercialize a subcutaneous formulation of teprotumumab to treat Thyroid Eye Disease.
Under the exclusive worldwide license deal, the new formulation will use Xeris' XeriJect technology.
Xeris may get up to $75 million in development and regulatory milestones, as well as sales-based milestones and "escalating single-digit royalties."
Amgen owns teprotumumab, which goes by brand name Tepezza, after closing its $27.8 billion acquisition of Horizon Therapeutics.
Write to Ben Glickman at ben.glickman@wsj.com
(END) Dow Jones Newswires
January 10, 2024 09:57 ET (14:57 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What History Tells Us About the Fed’s Next Move
-
What’s Happening In the Markets This Week
-
Alphabet’s New Dividend: What Investors Need to Know
-
Going Into Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
Going Into Earnings, Is Eli Lilly Stock a Buy, a Sell, or Fairly Valued?
-
What’s the Difference Between the CPI and PCE Indexes?
-
5 Stocks to Buy That We Still Like After They’ve Run Up
-
Markets Brief: Stocks Are Starting to Look Cheap Again
-
AbbVie Earnings: Next-Generation Immunology Drugs Help Offset Humira Biosimilar Pressure
-
Exxon Earnings: Ignore Earnings Shortfall as Long-Term Growth and Improvement on Track
-
American Airlines Earnings: We See Costs Overshadowing Market Share This Year
-
Snap Earnings: Advertising Growth and Snapchat+ Drive Monetization
-
STMicro Earnings: We Still See an Attractive Margin of Safety Despite a Poor First-Half Forecast
-
Alphabet Shares Surge on Strong Earnings, Dividend Surprise
-
Microsoft Earnings: Firm Beats Forecasts on Strong AI and Cloud Demand
-
PG&E Earnings: Near-Term Regulatory Certainty Supports Industry-Leading Earnings Growth